Application of the selective bcl-2 inhibitor venetoclax in hematologic malignancies
10.3760/cma.j.cn115356-20200519-00136
- VernacularTitle:选择性bcl-2抑制剂——维奈托克在血液肿瘤中的应用
- Author:
Yejun RUAN
1
;
Jie XIAO
;
Liping MA
Author Information
1. 中山大学孙逸仙纪念医院血液科，广州 510120
- From:
Journal of Leukemia & Lymphoma
2020;29(11):695-698
- CountryChina
- Language:Chinese
-
Abstract:
Resistance to apoptosis is a key carcinogenic mechanism in hematologic malignancies. bcl-2 is considered to be an important anti-apoptotic protein of endogenous apoptosis pathway and bcl-2 targeting inhibition has become one of research hotspots of anti-hematologic malignancies. Venetoclax, a selective bcl-2 inhibitor, has been used in the treatment of chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and mantle cell lymphoma (MCL). This paper reviews the role of bcl-2 family in the regulation of apoptosis and advances of venetoclax in hematologic malignancies.
